Larimar registers Phase 3 FORWARD-FA trial of nomlabofusp for Friedreich's ataxia

This week's update centers on a single new registry entry for Larimar Therapeutics' lead program in Friedreich's ataxia.

• Larimar Therapeutics has registered a Phase 3, randomized, double-blind, placebo-controlled study called FORWARD-FA testing subcutaneous nomlabofusp in adults and children with Friedreich's ataxia.¹ The trial's status is recruiting, with an estimated primary completion in July 2029 and study completion in December 2029, and it plans to enroll 150 participants (estimated)¹. The primary outcomes measure change from baseline at Week 72 in the Upright Stability Score subscale of the modified Friedreich's Ataxia Rating Scale and in the total mFARS score.¹ A secondary outcome tracks change in the Clinical Global Impression-Severity score at Week 72.¹ Nomlabofusp, also known as CTI-1601, is described as a recombinant fusion protein delivered by subcutaneous injection intended to supply human frataxin, the protein deficient in Friedreich's ataxia.¹